How consistent is the relationship between improved glucose control and modelled health outcomes for people with type 2 diabetes mellitus? a systematic review

Xinyang Hua, Thomas Wai-Chun Lung, Andrew Palmer, Lei Si, William H. Herman, Philip Clarke

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Background: There are an increasing number of studies using simulation models to conduct cost-effectiveness analyses for type 2 diabetes mellitus. Objective: To evaluate the relationship between improvements in glycosylated haemoglobin (HbA1c) and simulated health outcomes in type 2 diabetes cost-effectiveness studies. Methods: A systematic review was conducted on MEDLINE and EMBASE to collect cost-effectiveness studies using type 2 diabetes simulation models that reported modelled health outcomes of blood glucose-related interventions in terms of quality-adjusted life-years (QALYs) or life expectancy (LE). The data extracted included information used to characterise the study cohort, the intervention’s treatment effects on risk factors and model outcomes. Linear regressions were used to test the relationship between the difference in HbA1c (∆HbA1c) and incremental QALYs (∆QALYs) or LE (∆LE) of intervention and control groups. The ratio between the ∆QALYs and ∆LE was calculated and a scatterplot between the ratio and ∆HbA1c was used to explore the relationship between these two. Results: Seventy-six studies were included in this research, contributing to 124 pair of comparators. The pooled regressions indicated that the marginal effect of a 1% HbA1c decrease in intervention resulted in an increase in life-time QALYs and LE of 0.371 (95% confidence interval 0.286–0.456) and 0.642 (95% CI 0.494–0.790), respectively. No evidence of heterogeneity between models was found. An inverse exponential relationship was found and fitted between the ratio (∆QALY/∆LE) and ∆HbA1c. Conclusion: There is a consistent relationship between ∆HbA1c and ∆QALYs or ∆LE in cost-effectiveness analyses using type 2 diabetes simulation models. This relationship can be used as a diagnostic tool for decision makers.

LanguageEnglish
Pages319-329
Number of pages11
JournalPharmacoEconomics
Volume35
Issue number3
DOIs
Publication statusPublished - 1 Mar 2017
Externally publishedYes

Fingerprint

Life Expectancy
Quality-Adjusted Life Years
Type 2 Diabetes Mellitus
Glucose
Health
Cost-Benefit Analysis
Glycosylated Hemoglobin A
MEDLINE
Blood Glucose
Linear Models
Cohort Studies
Quality of Life
Confidence Intervals
Control Groups
Research

Cite this

Hua, Xinyang ; Lung, Thomas Wai-Chun ; Palmer, Andrew ; Si, Lei ; Herman, William H. ; Clarke, Philip. / How consistent is the relationship between improved glucose control and modelled health outcomes for people with type 2 diabetes mellitus? a systematic review. In: PharmacoEconomics. 2017 ; Vol. 35, No. 3. pp. 319-329.
@article{737ba77e693145e6b8a1846243ef2c8e,
title = "How consistent is the relationship between improved glucose control and modelled health outcomes for people with type 2 diabetes mellitus? a systematic review",
abstract = "Background: There are an increasing number of studies using simulation models to conduct cost-effectiveness analyses for type 2 diabetes mellitus. Objective: To evaluate the relationship between improvements in glycosylated haemoglobin (HbA1c) and simulated health outcomes in type 2 diabetes cost-effectiveness studies. Methods: A systematic review was conducted on MEDLINE and EMBASE to collect cost-effectiveness studies using type 2 diabetes simulation models that reported modelled health outcomes of blood glucose-related interventions in terms of quality-adjusted life-years (QALYs) or life expectancy (LE). The data extracted included information used to characterise the study cohort, the intervention’s treatment effects on risk factors and model outcomes. Linear regressions were used to test the relationship between the difference in HbA1c (∆HbA1c) and incremental QALYs (∆QALYs) or LE (∆LE) of intervention and control groups. The ratio between the ∆QALYs and ∆LE was calculated and a scatterplot between the ratio and ∆HbA1c was used to explore the relationship between these two. Results: Seventy-six studies were included in this research, contributing to 124 pair of comparators. The pooled regressions indicated that the marginal effect of a 1{\%} HbA1c decrease in intervention resulted in an increase in life-time QALYs and LE of 0.371 (95{\%} confidence interval 0.286–0.456) and 0.642 (95{\%} CI 0.494–0.790), respectively. No evidence of heterogeneity between models was found. An inverse exponential relationship was found and fitted between the ratio (∆QALY/∆LE) and ∆HbA1c. Conclusion: There is a consistent relationship between ∆HbA1c and ∆QALYs or ∆LE in cost-effectiveness analyses using type 2 diabetes simulation models. This relationship can be used as a diagnostic tool for decision makers.",
author = "Xinyang Hua and Lung, {Thomas Wai-Chun} and Andrew Palmer and Lei Si and Herman, {William H.} and Philip Clarke",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s40273-016-0466-0",
language = "English",
volume = "35",
pages = "319--329",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "3",

}

How consistent is the relationship between improved glucose control and modelled health outcomes for people with type 2 diabetes mellitus? a systematic review. / Hua, Xinyang; Lung, Thomas Wai-Chun; Palmer, Andrew; Si, Lei; Herman, William H.; Clarke, Philip.

In: PharmacoEconomics, Vol. 35, No. 3, 01.03.2017, p. 319-329.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - How consistent is the relationship between improved glucose control and modelled health outcomes for people with type 2 diabetes mellitus? a systematic review

AU - Hua, Xinyang

AU - Lung, Thomas Wai-Chun

AU - Palmer, Andrew

AU - Si, Lei

AU - Herman, William H.

AU - Clarke, Philip

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background: There are an increasing number of studies using simulation models to conduct cost-effectiveness analyses for type 2 diabetes mellitus. Objective: To evaluate the relationship between improvements in glycosylated haemoglobin (HbA1c) and simulated health outcomes in type 2 diabetes cost-effectiveness studies. Methods: A systematic review was conducted on MEDLINE and EMBASE to collect cost-effectiveness studies using type 2 diabetes simulation models that reported modelled health outcomes of blood glucose-related interventions in terms of quality-adjusted life-years (QALYs) or life expectancy (LE). The data extracted included information used to characterise the study cohort, the intervention’s treatment effects on risk factors and model outcomes. Linear regressions were used to test the relationship between the difference in HbA1c (∆HbA1c) and incremental QALYs (∆QALYs) or LE (∆LE) of intervention and control groups. The ratio between the ∆QALYs and ∆LE was calculated and a scatterplot between the ratio and ∆HbA1c was used to explore the relationship between these two. Results: Seventy-six studies were included in this research, contributing to 124 pair of comparators. The pooled regressions indicated that the marginal effect of a 1% HbA1c decrease in intervention resulted in an increase in life-time QALYs and LE of 0.371 (95% confidence interval 0.286–0.456) and 0.642 (95% CI 0.494–0.790), respectively. No evidence of heterogeneity between models was found. An inverse exponential relationship was found and fitted between the ratio (∆QALY/∆LE) and ∆HbA1c. Conclusion: There is a consistent relationship between ∆HbA1c and ∆QALYs or ∆LE in cost-effectiveness analyses using type 2 diabetes simulation models. This relationship can be used as a diagnostic tool for decision makers.

AB - Background: There are an increasing number of studies using simulation models to conduct cost-effectiveness analyses for type 2 diabetes mellitus. Objective: To evaluate the relationship between improvements in glycosylated haemoglobin (HbA1c) and simulated health outcomes in type 2 diabetes cost-effectiveness studies. Methods: A systematic review was conducted on MEDLINE and EMBASE to collect cost-effectiveness studies using type 2 diabetes simulation models that reported modelled health outcomes of blood glucose-related interventions in terms of quality-adjusted life-years (QALYs) or life expectancy (LE). The data extracted included information used to characterise the study cohort, the intervention’s treatment effects on risk factors and model outcomes. Linear regressions were used to test the relationship between the difference in HbA1c (∆HbA1c) and incremental QALYs (∆QALYs) or LE (∆LE) of intervention and control groups. The ratio between the ∆QALYs and ∆LE was calculated and a scatterplot between the ratio and ∆HbA1c was used to explore the relationship between these two. Results: Seventy-six studies were included in this research, contributing to 124 pair of comparators. The pooled regressions indicated that the marginal effect of a 1% HbA1c decrease in intervention resulted in an increase in life-time QALYs and LE of 0.371 (95% confidence interval 0.286–0.456) and 0.642 (95% CI 0.494–0.790), respectively. No evidence of heterogeneity between models was found. An inverse exponential relationship was found and fitted between the ratio (∆QALY/∆LE) and ∆HbA1c. Conclusion: There is a consistent relationship between ∆HbA1c and ∆QALYs or ∆LE in cost-effectiveness analyses using type 2 diabetes simulation models. This relationship can be used as a diagnostic tool for decision makers.

UR - http://www.scopus.com/inward/record.url?scp=84996528943&partnerID=8YFLogxK

U2 - 10.1007/s40273-016-0466-0

DO - 10.1007/s40273-016-0466-0

M3 - Review article

VL - 35

SP - 319

EP - 329

JO - PharmacoEconomics

T2 - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 3

ER -